Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
16
datasets available to search
ShareScore release 0.9.0
Dataset results
16 results for “Extensively drug resistance”
The repurposing of tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug resistant Shigella spp.
<p><strong>dataset for The repurposing of tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug resistant <em>Shigella</em> spp.</strong></p> <p>Elena Fernández Alvaro <sup>1*</sup>, Phat Voong Vinh <sup>2</sup>, Cristina de Cozar <sup>1</sup>, David Wille <sup>1</sup>, Beatriz Urones <sup>1</sup>,</p> <p>Alan Price <sup>1</sup>, Nhu Tran Do Hoang <sup>2</sup>, Tuyen Ha Thanh <sup>2</sup>, Molly McCloskey <sup>3</sup>, Shareef Shaheen<sup> 3</sup>, Denise Dayao<sup> 4</sup>, Jaime de Mercado <sup>1</sup>, Pablo Castañeda <sup>1</sup>, Adolfo García-Perez <sup>1</sup>, Benson Singa <sup>5</sup>, Patricia Pavlinac <sup>6</sup>,</p> <p>Judd Walson<sup>3</sup>, Maria Santos Martínez-Martínez <sup>1</sup>, Samuel L.M. Arnold <sup>3</sup>, Tzipori Saul <sup>4</sup>, Lluis Ballell <sup>1#</sup>,</p> <p>and Stephen Baker <sup>7,8*</sup></p> <p> </p>
Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: retrospective cohort study
<p><strong>Abstract</strong></p> <p><strong>Background</strong>: Extensively drug-resistant tuberculosis (XDR TB) is a very serious form of tuberculosis that is burdened with a heavy mortality toll, especially before the advent of new TB drugs. The Democratic Republic of the Congo (DRC) is among the countries most affected by this new epidemic.</p> <p><strong>Methods:</strong> A retrospective analysis was performed of the records of all patients with pre- and extensively drug-resistant tuberculosis hospitalized from January 1, 2015 to December 31, 2017 and monitored for at least 6 months to one year after the end of their treatment in Kinshasa; an individualized therapeutic regimen with bedaquiline for 20 months was built for each patient. The adverse effects were systematically monitored.</p> <p><strong>Results:</strong> Of the 40 laboratory-confirmed patients, 32 (80%) patients started treatment, including 29 preXRB and 3 XDR TB patients. In the eligible group, 3 patients (9.4%) had HIV-TB coinfections. The therapeutic success rate was 53.2%, and the mortality rate was 46.8% (15/32); there were no relapses, failures or losses to follow-up. All coinfected HIV–TB patients died during treatment. The cumulative patient survival rate was 62.5% at 3 months, 53.1% at 6 months and 53.1% at 20 months. The most common adverse events were vomiting, Skin rash, anemia and peripheral neuropathy.</p> <p><strong>Conclusion: </strong>Bedaquiline based treatment improves patient survival in the DRC despite the still high mortality rate. The new anti-tuberculosis<br> drugs are a real hope for the management of Drug Resistant tuberculosis patient and other new therapeutic combinations may improve favorable outcomes.</p>
Linezolid to Treat Extensively-Drug Resistant Tuberculosis
ClinicalTrials.gov study NCT00727844. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
ClinicalTrials.gov study NCT01597973. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: retrospective cohort study
Open the record for dataset details and reuse information.
Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria
ClinicalTrials.gov study NCT02328183. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
ClinicalTrials.gov study NCT02519439. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii
ClinicalTrials.gov study NCT03622918. IPD Sharing: UNDECIDED. Countries: 0. Publications: 1.
An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
ClinicalTrials.gov study NCT02625090. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
ClinicalTrials.gov study NCT01963208. IPD Sharing: Not stated. Countries: 6. Publications: 0.
Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.
ClinicalTrials.gov study NCT04352855. IPD Sharing: NO. Countries: 1. Publications: 0.
A Multidrug-resistant (MDR) and Extensively Drug- Resistant (XDR) Tuberculosis Study in Alsace
ClinicalTrials.gov study NCT03507816. IPD Sharing: NO. Countries: 1. Publications: 0.
Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis
ClinicalTrials.gov study NCT01464762. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Expression profiling of extensively drug-resistant tuberculosis isolates and H37Rv exposed to anti-TB compounds
GEO Series GSE53843. Mycobacterium tuberculosis H37Rv; Mycobacterium tuberculosis. 12 samples. Type: Expression profiling by array.
Mycobacterium tuberculosis clinical isolates in China: extensively drug-resistant tuberculosis vs drug sensitive one
GEO Series GSE15540. Mycobacterium tuberculosis. 1 samples. Type: Expression profiling by array.
THP-1 cells infected with the clinical isolates of extensively drug-resistant and drug sensitive tuberculosis
GEO Series GSE15539. Homo sapiens. 4 samples. Type: Expression profiling by array.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.